A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.

Diamond, M P; Stewart, E A; Williams, A R W; Carr, B R; Myers, E R; Feldman, R A; Elger, W; Mattia-Goldberg, C; Schwefel, B M; Chwalisz, K

Diamond, M P; Stewart, E A; Williams, A R W; Carr, B R; Myers, E R; Feldman, R A; Elger, W; Mattia-Goldberg, C; Schwefel, B M; Chwalisz, K.

Afiliación

Diamond MP; Department of Obstetrics & Gynecology, Augusta University, Augusta, GA 30912, USA.
Stewart EA; Departments of Obstetrics & Gynecology and Surgery, Mayo Clinic and Mayo Medical School, Rochester, MN 55905, USA.
Williams ARW; Department of Pathology, University of Edinburgh, Edinburgh, UK.
Carr BR; Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Myers ER; Department of Obstetrics & Gynecology, Duke University Medical Center, Durham, NC 27710, USA.
Feldman RA; Miami Research Associates, Miami, FL 33143, USA.
Elger W; Evestra GmbH, Berlin-Dahlem, Germany.
Mattia-Goldberg C; AbbVie Inc., North Chicago, IL 60064, USA.
Schwefel BM; AbbVie Inc., North Chicago, IL 60064, USA.
Chwalisz K; AbbVie Inc., North Chicago, IL 60064, USA.

Hum Reprod Open ; 2019(4): hoz027, 2019.

Article en En | MEDLINE | ID: mdl-31777761

Palabras clave

J867; asoprisnil; selective progesterone receptor modulator; uterine fibroids; uterine leiomyoma; uterine leiomyomata

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Aspecto: Patient_preference Idioma: En Revista: Hum Reprod Open Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google